65,437 trials
Rheumatoid Arthritis
Primary: Dose of NSAID — 319.72; 301.58 mg
ADHD
Primary: Percent of Participants With Treatment Failures at End of The Randomized Withdrawal Period — 15.8; 67.5 percentage of participants — p=< 0.001
Liver Carcinoma
Primary: Percentage of Participants Surviving at One and Four Years After Liver Transplant — 85; 77 percentage of participants
Facial Wrinkles
Primary: Number of Participants With Effectiveness and Safety Success — 30; 41 participants
Colonic Polyps · Colonic Neoplasms
Primary: Boston Bowel Preparation Scale Score — 6; 6 units on a scale
Neoplasms, Gastrointestinal Tract
Primary: Change From Start of Run-in Period in Biomarker Expression Levels at Day 0 — 0.38; 0.12; 0.15; 0.01 ratio — p=0.10
Panic Disorder · Depression
Primary: Number of Participants of Treatment Related Adverse Events (TRAEs) — 263 participants
Myeloproliferative Disorders · Kidney Cancer · Leukemia
Primary: Achievement of > 90% (Full) Donor Chimerism in the T-cell Lineage as Measured by PCR at Day 30 Post-transplantation — 12 participants
Head and Neck Cancer
Primary: Overall Survival — 8 months
Peripheral Vascular Disease
Primary: Major Adverse Event (MAE) — 5.4 percentage of participants
Healthy
Primary: % Platelet Inhibition — 23.4; 24.6; 41.2; 59 percentage of platelet inhibition
Non Small Cell Lung Carcinoma
Primary: Objective Response Rate(ORR) — 31.2 Percent of participants
Stage I Multiple Myeloma · Stage II Multiple Myeloma · Stage III Multiple Myeloma
Primary: Response Rate on Induction — 47.6 percentage of participants
Heart Failure · Diabetes
Primary: Effect of Thiamine Supplementation on Dyspnea — 34; 32 mm
Pain · Peripheral Neuropathy
Primary: Change From Baseline in the Mean Daily Peripheral Neuropathic Pain on a 0-10 Numerical Rating Scale Score During the Last Seven Days of Treatment (End of Treatment)…